Pasithea Therapeutics Warrants
KTTAW
5 hedge funds and large institutions have $8.8K invested in Pasithea Therapeutics Warrants in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 0 reducing their positions, and 2 closing their positions.
8% less capital invested
Capital invested by funds: $9.59K → $8.8K (-$789)
17% less funds holding
Funds holding: 6 → 5 (-1)
33.86% less ownership
Funds ownership: 49.55% → 15.69% (-34%)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$307 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$2.03K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$193 |
KTTAW Hedge Fund Activity: Q2 2025 in Review
5 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics Warrants (KTTAW) for Q2 2025, worth a combined $8.8K — down 8.2% from $9.59K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of KTTAW and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $307. The largest seller was Warberg Asset Management, exiting entirely with an estimated $2.03K sold.
- 5 institutional investors held Pasithea Therapeutics Warrants (KTTAW) as of Q2 2025, down from 6 in Q1 2025.
- Funds reported $8.8K of Pasithea Therapeutics Warrants stock for Q2 2025, down 8.2% quarter-over-quarter.
- 1 fund opened new Pasithea Therapeutics Warrants positions in Q2 2025 and 2 closed out, a net change of -1 holder.
- The largest Pasithea Therapeutics Warrants buyer in Q2 2025 was Citadel Advisors, an estimated $307 added.
- The largest Pasithea Therapeutics Warrants seller in Q2 2025 was Warberg Asset Management, an estimated $2.03K sold.
Based on aggregated 13F filings for Q2 2025.